Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats
Aiman A Jafri1, Suman B Sharma1*, Usha R Singh2, Kalpana Luthra3
Affiliation
- 1Department of Biochemistry, University College of Medical Sciences (University of Delhi), Dilshad Garden, Delhi, India
- 2Department of Pathology, University College of Medical Sciences (University of Delhi), Dilshad Garden, Delhi, India
- 3Department of Biochemistry, All India institute of Medical Sciences, Ansari Nagar, New Delhi
Corresponding Author
Suman, B. Sharma, Department of Biochemistry, University College of Medical Sciences (University of Delhi), Dilshad Garden, Delhi- 110095, Tel: +91- 9818041119; E-mail: drsbs08@hotmail.com
Citation
Sharma, S.B., et al. Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats. (2016) J Diabetes Obes 3(1): 27-32.
Copy rights
© 2016 Sharma, S.B. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Objective: To study the effect of HPLC purified herbal anti-hyperglycemic active compound (FIIc) isolated from the fruit pulp of Eugenia jambolana in diabetic rats.
Methods: 24 male wistar rats were taken and diabetes was induced in group B, C and D rats (n = 6 each) by injecting Streptozotocin at a dose of 45 mg/kg of body weight 15 minutes after Nicotinamide at a dose 230 mg/kg body weight intraperitoneally after overnight fasting. Active compound (FIIc) was given to group C and Pioglitazone to group D at dose of 20 mg/kg of body weight orally for 4 weeks respectively. Glycemic and lipid profile, protein tyrosine kinase activity and serum DPP-4 levels were measured and compared between all the 4 study groups.
Results: Significant Improvement in body weight, glycemic profile, dyslipidemia and tyrosine kinase activity (4.90 ± 1.28 U/mg protein) were observed in FIIc treated rats at week 4 of the study compared to diabetic control rats. Serum DPP-4 levels (26.41 ± 0.43 pg/ml) were also found to be decreased in FIIc treated rats at week 4 of the study compared to diabetic control rats. This is possibly due to increased serum insulin levels and increased insulin sensitivity after treatment with active compound FIIc.
Conclusion: FIIc significantly reduced hyperglycemia and dyslipidemia by inhibiting DPP-4 levels and improves insulin sensitivity by increasing protein tyrosine kinase activity and serum insulin levels.